Cartesian Therapeutics, Inc. Deferred Income Tax Expense (Benefit)
Cartesian Therapeutics, Inc. (RNAC) reported Deferred Income Tax Expense (Benefit) of -$9.19 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-09.
Financial Statements › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2026-03-09
- Cartesian Therapeutics, Inc. deferred income tax expense (benefit) for the quarter ending 2018-12-31 was $0.00.
- Cartesian Therapeutics, Inc. deferred income tax expense (benefit) for the quarter ending 2018-09-30 was $0.00.
- Cartesian Therapeutics, Inc. deferred income tax expense (benefit) for the quarter ending 2018-06-30 was $0.00.
- Cartesian Therapeutics, Inc. deferred income tax expense (benefit) for the quarter ending 2018-03-31 was $0.00.
- Cartesian Therapeutics, Inc. deferred income tax expense (benefit) for fiscal 2025 was -$9.19M, a 3303.14% decline from fiscal 2024.
- Cartesian Therapeutics, Inc. deferred income tax expense (benefit) for fiscal 2024 was $287.00K.
- Cartesian Therapeutics, Inc. deferred income tax expense (benefit) for fiscal 2023 was -$19.00M.
- Cartesian Therapeutics, Inc. deferred income tax expense (benefit) for fiscal 2022 was $0.00.
| Period end | Deferred Income Tax Expense (Benefit) 3 month | Deferred Income Tax Expense (Benefit) 6 month | Deferred Income Tax Expense (Benefit) 9 month | Deferred Income Tax Expense (Benefit) 12 month |
|---|---|---|---|---|
| 2025-12-31 | -$9.19M 10-K · filed 2026-03-09 | |||
| 2024-12-31 | $287.00K 10-K · filed 2026-03-09 | |||
| 2023-12-31 | -$19.00M 10-K · filed 2025-03-13 | |||
| 2022-12-31 | $0.00 10-K · filed 2024-03-07 | |||
| 2021-12-31 | $0.00 10-K · filed 2024-03-07 | |||
| 2018-12-31 | $0.00 10-K · filed 2019-03-15 | $0.00 derived: sum of 2 quarters · filed 2019-03-15 | $0.00 derived: sum of 3 quarters · filed 2019-03-15 | $0.00 10-K · filed 2019-03-15 |
| 2018-09-30 | $0.00 10-Q · filed 2018-11-08 | $0.00 derived: sum of 2 quarters · filed 2018-11-08 | $0.00 10-Q · filed 2018-11-08 | $0.00 derived: sum of 4 quarters · filed 2019-03-15 |
| 2018-06-30 | $0.00 10-Q · filed 2018-08-08 | $0.00 10-Q · filed 2018-08-08 | $0.00 derived: sum of 3 quarters · filed 2019-03-15 | $0.00 derived: sum of 4 quarters · filed 2019-03-15 |
| 2018-03-31 | $0.00 10-Q · filed 2018-05-09 | $0.00 derived: sum of 2 quarters · filed 2019-03-15 | $0.00 derived: sum of 3 quarters · filed 2019-03-15 | $0.00 derived: sum of 4 quarters · filed 2019-03-15 |
| 2017-12-31 | $0.00 10-K · filed 2019-03-15 | $0.00 derived: sum of 2 quarters · filed 2019-03-15 | $0.00 derived: sum of 3 quarters · filed 2019-03-15 | $0.00 10-K · filed 2019-03-15 |
| 2017-09-30 | $0.00 10-Q · filed 2018-11-08 | $0.00 derived: sum of 2 quarters · filed 2018-11-08 | $0.00 10-Q · filed 2018-11-08 | |
| 2017-06-30 | $0.00 10-Q · filed 2018-08-08 | $0.00 10-Q · filed 2018-08-08 | ||
| 2017-03-31 | $0.00 10-Q · filed 2018-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |